Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 6/1998

01-12-1998 | Original Article

Postoperative adjuvant chemotherapy with mitomycin C and UFT for curatively resected rectal cancer. Results from the Cooperative Project No.7 Group of the Japanese Foundation for Multidisciplinary Treatment of Cancer

Authors: S. Kodaira, K. Kikuchi, Y. Kunii, M. Yasutomi, T. Takahashi, K. Hojo, T. Kato, T. Tominaga

Published in: International Journal of Clinical Oncology | Issue 6/1998

Login to get access
Metadata
Title
Postoperative adjuvant chemotherapy with mitomycin C and UFT for curatively resected rectal cancer. Results from the Cooperative Project No.7 Group of the Japanese Foundation for Multidisciplinary Treatment of Cancer
Authors
S. Kodaira
K. Kikuchi
Y. Kunii
M. Yasutomi
T. Takahashi
K. Hojo
T. Kato
T. Tominaga
Publication date
01-12-1998
Publisher
Springer-Verlag
Published in
International Journal of Clinical Oncology / Issue 6/1998
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/BF00539213

Other articles of this Issue 6/1998

International Journal of Clinical Oncology 6/1998 Go to the issue

Original Article

High-dose-rate brachytherapy using molds for oral cavity cancer: The technique and its limitations

Case Report

Immunohistochemical study of HLA antigens and lymphocytic infiltrations in advanced vaginal cancer regressed by adjuvant therapy with intratumoral sizofiran

Original Article

Patterns of care study of radiation therapy for esophageal cancer in Japan: influence of age on parameters of treatment

Original Article

Influence of truth disclosure on quality of life in cancer patients

Acknowledgments

Acknowledgments

Case Report

Recurrent angiosarcoma effectively treated with superselective continuous intra-arterial injection of recombinant interleukin-2 combined with radiotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits